BXM Wealth LLC Takes $231,000 Position in Danaher Co. (NYSE:DHR)

BXM Wealth LLC acquired a new stake in Danaher Co. (NYSE:DHR) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 1,005 shares of the conglomerate’s stock, valued at approximately $231,000.

A number of other large investors have also added to or reduced their stakes in DHR. Heck Capital Advisors LLC bought a new position in shares of Danaher in the fourth quarter valued at approximately $27,000. Decker Retirement Planning Inc. purchased a new position in shares of Danaher in the fourth quarter worth $31,000. Golden State Wealth Management LLC purchased a new position in Danaher during the 4th quarter valued at $31,000. Strategic Financial Concepts LLC bought a new stake in shares of Danaher during the 4th quarter valued at $31,000. Finally, Pineridge Advisors LLC boosted its holdings in shares of Danaher by 63.3% during the 4th quarter. Pineridge Advisors LLC now owns 147 shares of the conglomerate’s stock valued at $34,000 after buying an additional 57 shares in the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Insiders Place Their Bets

In other Danaher news, SVP Brian W. Ellis sold 5,700 shares of the company’s stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $224.13, for a total transaction of $1,277,541.00. Following the transaction, the senior vice president now owns 20,230 shares of the company’s stock, valued at approximately $4,534,149.90. This represents a 21.98 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 11.10% of the company’s stock.

Danaher Trading Up 1.5 %

Shares of DHR opened at $206.66 on Friday. Danaher Co. has a 12-month low of $196.80 and a 12-month high of $281.70. The company has a quick ratio of 1.05, a current ratio of 1.40 and a debt-to-equity ratio of 0.31. The firm has a market capitalization of $149.26 billion, a price-to-earnings ratio of 39.14, a P/E/G ratio of 2.68 and a beta of 0.83. The stock’s 50-day moving average price is $230.00 and its 200 day moving average price is $249.96.

Danaher (NYSE:DHR) last released its quarterly earnings data on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share for the quarter, meeting the consensus estimate of $2.14. Danaher had a return on equity of 10.82% and a net margin of 16.33%. During the same period last year, the company posted $2.09 EPS. As a group, research analysts predict that Danaher Co. will post 7.67 earnings per share for the current year.

Danaher Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, January 31st. Shareholders of record on Friday, December 27th were issued a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a yield of 0.52%. The ex-dividend date of this dividend was Friday, December 27th. Danaher’s dividend payout ratio is 20.45%.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on DHR. Bank of America raised shares of Danaher from a “neutral” rating to a “buy” rating and set a $290.00 price target for the company in a research report on Friday, December 13th. JPMorgan Chase & Co. dropped their price objective on shares of Danaher from $310.00 to $300.00 and set an “overweight” rating for the company in a research note on Tuesday, January 28th. Stifel Nicolaus lifted their target price on Danaher from $250.00 to $265.00 and gave the stock a “hold” rating in a research report on Wednesday, October 23rd. Barclays decreased their price objective on Danaher from $275.00 to $240.00 and set an “equal weight” rating for the company in a report on Thursday, January 30th. Finally, KeyCorp boosted their price target on Danaher from $290.00 to $310.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 23rd. Seven equities research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $278.00.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.